HJ Science Co., Ltd. (HKG:6132)

Market Cap	2.37B
Revenue (ttm)	16.30M +407.8%
Net Income	-179.65M
EPS	-2.98
Shares Out	73.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	135,900
Open	33.90
Previous Close	34.94
Day's Range	31.10 - 34.50
52-Week Range	30.00 - 82.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About HJ Science

HJ Science Co., Ltd. engages in research and development of new small molecule drugs. The company focuses on metabolic diseases, oncology, and autoimmune disorders. The company’s core product pipeline includes HJ787, a selective TYK2 inhibitor intended for the treatment of atopic dermatitis (AD) and acne vulgaris (AV); HJ178, an orally available agent for type 2 diabetes; and HJ891, an oral KRAS inhibitor and intravenous injection intended for the treatment of non-small-cell lung cancer (NSCLC). It is also developing HJ197 in clinical-stage for...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 113
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6132

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error